anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine; immunology.SUBSTANCE: group of inventions is intended for treating a disease mediated by type 5 CXC chemokine receptor. Antibody formulation suitable for subcutaneous administration to a patient and used for treating type 5 CXC chemokine receptor mediated disease, contains an antibody, a citrate buffer, polysorbate 20 or polysorbate 80, arginine and sucrose. Components are used in the declared amounts, and the pH value of the composition is approximately 6. Antibody is a fully human anti-CXCR5 antibody, containing a heavy chain with the amino acid sequence SEQ ID NO: 33 and light chain with amino acid sequence SEQ ID NO: 32. In other embodiments, containers and kits comprising said composition are provided. Also disclosed is a method of treating rheumatoid arthritis, involving administering to a subject in need thereof a therapeutically effective amount of said antibody composition.EFFECT: use of the group of the invention provides prolonged stability of the antibody formulations during storage in glass containers.13 cl, 9 tbl, 2 ex, 20 dwg
Title To formulate and see efficacy of passive oral motor regimen for drooling in children with multiple disabilities Background Drooling ranges from mild embarrassment and discomfort for the intellectually intact patient with minimal drooling to gross emotional and physical impairment for the severely affected individual. Drooling produces an unhygienic condition that may be associated with a disagreeable odour. Drooling affects the social and physical wellbeing of children and may represent problems for caregivers. Many persons with severe and profound disabilities exhibit chronic and excessive drooling, which can have unfavourable effects on their socialization and health. Studies have suggested that various treatments like medication, surgery, behaviour modification, myofunctional therapy and oral motor therapy are effective in treating drooling but there is no single protocol developed to treat drooling in children with multiple disabilities. Passive treatment protocol is needed specifically designed for children who are not able to follow commands and on whom various treatment techniques like behaviour modification, over-correction can't be applied. Present study aims to formulate and see the efficacy of passive oral motor regimen for drooling in children with multiple disabilities.

Methodology Seven subjects of age group between 07-19 years were selected out of accessible population.

Informed consent taken from the parents/caregivers.Severity and frequency of drooling accessed (For each subject prior to the study) and Drool Quotient was calculated (For each subject prior to the study). Patient was in sitting position with back fully supported and head in neutral position in their own home. Therapist in standing position in front of the patient.Therapist wore sterilised gloves to ensure that no infection occurs along with change of gloves for every subject. Light touch applied to mid line of lips (3 times, for 5 sec). Maintained pressure applied around lips (3 times for 3 sec). Gentle tapping to the cheeks applied with index finger (8 times each cheek). Quick, gentle stretch applied outward with index and middle finger on middle of upper lip and lower lip (8 times on each lip). Gentle stroke to the cheek applied with index finger from base of nose towards ear. Then returned back to corner of lips (8 times each cheek), repeat on the other side. Gentle stroking applied to area around the lips in a circular manner, from the corner towards the center and to the other corner, then reverse. (4 times each lip). Vibration slowly applied for 10-15 sec each of a) orbicularis oris b) Both sides of larynx from chin to sternal notch c) Under the chin from ear to ear.Quick stretch applied to the masseter muscles (3 times on each side). Stretch pressure applied to vibrated areas, on a) orbicularis oris b) Laryngopharyngeal muscles, both sides. Intra-orally applied light touch to roof of mouth, anteriorly for 3 times. The protocol was given for 4 weeks with treatment sessions given 3 times per week.

.
PURPOSE: To obtain the antitumor agent containing as an active ingredient a physiologically active substance which is produced from Sesquicillium globulisporum and which exists as a new isomer. CONSTITUTION: A microorganism (especially preferably Acremonium sp. NF 00364, FERM P-14273) belonging to the genus Acremonium and having an ability for producing a physiologically active substance: sesquicillin is cultured in a culture medium, and the physiologically active substance: sesquicillin, produced and accumulated in the culture solution is collected. The obtained sesquicillin is a new isomer (especially the specific rotation is +11.0 deg.). When the antitumor agent is used, the antitumor agent can be administered as an injection agent, an oral agent, a suppository, etc., singly or after mixed with an excipient or a carrier. The active ingredient in the preparation is preferably used in an amount of approximately 0.1-50wt.%. The physiologically active substance: sesquicillin has a multiplication-inhibiting action against various cancer cells and is relatively low toxic.
Personal cleansing compositions comprise (a) from about 5 wt. % to about 50 wt. % of a water-soluble detersive surfactant; (b) at least about 0.1 wt. % of a fiber having a length and a thickness such that said length is greater than said thickness, wherein said length is from about 5 μm to about 1.5 mm; and (c) at least about 20 wt. % of an aqueous carrier; wherein said fiber forms a load-sensitive deposit upon dilution of said personal cleansing composition with water. Methods of providing both increased volume and superior styling and conditioning to hair comprise applying the personal care composition as described above to the hair and rinsing the hair.
Early spontaneous abortion (ESA) is a common adverse pregnancy outcome mainly attributed to embryo chromosomal abnormalities. However, as a quantitative marker, whether the anti-Müllerian hormone (AMH) can reflect oocyte quality is still controversial. By integrating biological evidence and adjusting many cofounders, this study aimed to clarify the controversies about the association between AMH and ESA caused by embryo aneuploidy during assisted reproductive technology (ART) treatment. We strictly preselected 988 patients receiving first ART treatment for analyzing clinical data, while 55 of them acquired chorionic villi karyotype results. In addition, 373 biopsied embryos from 126 patients receiving preimplantation genetic diagnosis (PGT) were tracked to compare embryo karyotypes. Univariate and multiple factor regressions were applied to analyze the risk factors leading to ESA. As covariates unadjusted, AMH (odds ratio 0.87, 95% CI 0.82-0.93) was the significant variable contributing to ESA. However, AMH played no significant role in the following regression models after age was adjusted. Also, AMH had no significant association with ESA in most age-adjusted subgroups, except in the male factors engaged subgroup. Additionally, compared to the patients with euploid chorionic villi karyotypes, those with aneuploid karyotypes were older and acquired fewer oocytes, yet their AMH levels were not significantly different. Furthermore, the embryo aneuploidy was independent of AMH while associated with maternal age, retrieved oocyte number, and embryo quality. This study suggested that AMH was unassociated with the ESA caused by embryo aneuploidy in ART therapy. As a critical cofounder, age remains the variable closely related to ESA.
Prepn. of stable dispersions of at least one water-immiscible liq. (I) in an aq. medium (II) is carried out by (a) forming in the aq. medium a dispersion of "spherules" having an av. dia. of 0.025-5 microns and comprising an aq. phase (III) encapsulated between concentric layers of an ionic or nonionic amphiphilic material (IV) capable of forming a lamellar phase in water; (b) mixing the dispersion with (I); and (c) agitating the mixt. to disperse (I) in the aq. medium in the form of droplets with an av. dia. between 1 and a few microns. The process can be used to blood substitutes from perfluorinated cpds. or to prepare dispersions of intestinal lubricants, textile lubricants, foam inhibitors, cleansing agents, coating compsns. etc. The spherules stabilise the dispersion and are themselves stabilised by the droplets of (I).
INTRODUCTION: Excessive anxiety is a mental disorder, and its treatment involves the use of benzodiazepines, a class of drugs that enhance the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor. Anxiety disorders are frequent comorbidities in patients with epilepsy, and it has been speculated that anxiety disorders and epileptic seizures share common neurobiological mechanisms. However, conflicting results regarding anxiolytic and anxiogenic effects have been reported in animal models of epilepsy induced by pentylenetetrazole (PTZ) injections, and the causes of this discrepancy are unknown. We hypothesized that anxiety-like behaviors would change dynamically according to the changes in epilepsy susceptibility that occur during the PTZ kindling process. Therefore, we attempted to change anxiety-like behaviors bidirectionally depending on the number of PTZ injections.
METHODS: Adult male rats were injected with PTZ 20 times every other day, and stages of seizure onset were classified according to the Racine staging system. Anxiety-like behaviors were measured after 10 and 20 injections. The control group was injected with an equal volume of saline solution. Anxiety-like behaviors were investigated using the open-field, light/dark transition, elevated plus maze, and social interaction tests.
RESULTS: Bimodal changes in seizure stage were observed in response to PTZ kindling. The increase in the seizure stage was transiently suppressed after 10 injections, and this decrease in epileptic sensitivity disappeared after 20 injections. However, none of the rats reached a fully kindled state after 20 PTZ injections. After 10 PTZ injections, anxiety-like behaviors decreased compared with those of the control group in the open field, light/dark transition, and elevated plus-maze tests. The anxiolytic effects correlated with the seizure stage in individual rats. After 20 PTZ injections, anxiety-like behaviors returned to control levels.
CONCLUSION: PTZ kindling induced bimodal changes in the seizure stage. Anxiety-like behaviors decreased with transient decrease in epileptic sensitivity and returned to control levels with the disappearance of these states. These findings suggest a common neurobiological mechanism underlying anxiety disorders and epileptic seizures. In addition, the discrepancy in the previous studies, in which anxiety levels increase or decrease in PTZ-kindled animals, may be due to examination at different phases of the kindling process.
Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
UNLABELLED: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by an immunosuppressive tumor microenvironment enriched with cancer-associated fibroblasts (CAF). This study used a convergence approach to identify tumor cell and CAF interactions through the integration of single-cell data from human tumors with human organoid coculture experiments. Analysis of a comprehensive atlas of PDAC single-cell RNA sequencing data indicated that CAF density is associated with increased inflammation and epithelial-mesenchymal transition (EMT) in epithelial cells. Transfer learning using transcriptional data from patient-derived organoid and CAF cocultures provided in silico validation of CAF induction of inflammatory and EMT epithelial cell states. Further experimental validation in cocultures demonstrated integrin beta 1 (ITGB1) and vascular endothelial factor A (VEGFA) interactions with neuropilin-1 mediating CAF-epithelial cell cross-talk. Together, this study introduces transfer learning from human single-cell data to organoid coculture analyses for experimental validation of discoveries of cell-cell cross-talk and identifies fibroblast-mediated regulation of EMT and inflammation.
SIGNIFICANCE: Adaptation of transfer learning to relate human single-cell RNA sequencing data to organoid-CAF cocultures facilitates discovery of human pancreatic cancer intercellular interactions and uncovers cross-talk between CAFs and tumor cells through VEGFA and ITGB1.
During maintenance of anesthesia, etomidate will be given by target controlled infusion for 2 h first, and then propofol will be given by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml and 2 to 4 micrograms/ml, respectively. Bispectral index should be kept between 40 to 60.
PURPOSE OF REVIEW: This review will focus on the indications of mechanical circulatory support (MCS) for high-risk percutaneous coronary intervention (PCI) and then analyze in detail all MCS devices available to the operator, evaluating their mechanisms of action, pros and cons, contraindications, and clinical data supporting their use.
RECENT FINDINGS: Over the last decade, the interventional cardiology arena has witnessed an increase in the complexity profile of the patients and lesions treated in the catheterization laboratory. Patients with significant comorbidity burden, left ventricular dysfunction, impaired hemodynamics, and/or complex coronary anatomy often cannot tolerate extensive percutaneous revascularization. Therefore, a variety of MCS devices have been developed and adopted for high-risk PCI. Despite the variety of MCS available to date, a detailed characterization of the patient requiring MCS is still lacking. A precise selection of patients who can benefit from MCS support during high-risk PCI and the choice of the most appropriate MCS device in each case are imperative to provide extensive revascularization and improve patient outcomes. Several new devices are being tested in early feasibility studies and randomized clinical trials and the experience gained in this context will allow us to provide precise answers to these questions in the coming years.
Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
Participants will receive placebo in both deltoids at months 0, 1, 3, and 6. All injections are via needle and syringe.
PURPOSE: A composition containing garlic oil, gingko leaves extract, Crataegi Fructus extract, vitamin E, Eucommiae Cortex extract and Acanthopanacis senticosi Radix extract for improvement of blood circulation disorder is provided, which shows more excellent blood pressure dropping effect than a composition containing garlic oil, gingko leaves extract, Crataegi Fructus extract and vitamin E. CONSTITUTION: A process for the preparation of pills for improvement of blood circulation disorder comprises: mixing garlic oil 50-200wt.(0.05-0.15% as allicin), gingko leaves extract 10-50wt.(10-27% as gingkoflavone glycoside), Crataegi Fructus extract 20-100wt.(0.5-2% as hiperosid), vitamin E 10-50wt., Eucommiae Cortex extract 30-150wt.(0.02-0.12% as geniposidic acid), Acanthopanacis senticosi Radix extract 30-150wt.(0.1-0.45% as eleutheroside); shaping into pills by common pharmaceutical process. The composition for improvement of blood circulation disorder can be prepared in the form of tablets, soft capsules and suspension.
The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy, however, is not known.

One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. In vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). 

Although the relevance for human use is unknown, the following data characterize the performance of lamotrigine in receptor binding assays. Lamotrigine had a weak inhibitory effect on the serotonin 5-HT3 receptor (IC50= 18 µM). It does not exhibit high affinity binding (IC50>100 µM) to the following neurotransmitter receptors: adenosine A1 and A2; adrenergic α1, α2, and β; dopamine D1 and D2; γ-aminobutyric acid (GABA) A and B; histamine H1; kappa opioid; muscarinic acetylcholine; and serotonin 5-HT2. Studies have failed to detect an effect of lamotrigine on dihydropyridine-sensitive calcium channels. It had weak effects at sigma opioid receptors (IC50 = 145 µM). Lamotrigine did not inhibit the uptake of norepinephrine, dopamine, or serotonin, (IC50>200 µM) when tested in rat synaptosomes and/or human platelets in vitro.

Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity: Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCHP). The IC50 for lamotrigine effects on NMDA-induced currents (in the presence of 3 µM of glycine) in cultured hippocampal neurons exceeded 100 µM. 

The mechanisms by which lamotrigine exerts its therapeutic action in Bipolar Disorder have not been established.
The doctor would remove the inserted catheter from the patient, if the patient shows SIRS. At the same time, the tip of used catheter and blood from the patient are checked whether the pathogenic bacteria exists or not by general bacterial protocol and blood culture test on a routine application. Unfortunately, these tests not always clarified their cause of SIRS. Therefore we conduct this investigation to establish the useful protocol for pathogenic bacteria. We check the pathogenic bacteria not only tip but through the whole catheter in Central Venous Catheter using general bacterial protocol and SEM observation. Additionally, we compared that sputum, urine, skin and blood from the patient for bacteria check.
PLEASE REVIEW THE MANUFACTURER'S DATA, TABLES AND STUDIES HERE AT THE FDA SITE:

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a

Four placebo-controlled clinical studies and one active-controlled clinical study enrolled a total of 2296 patients (1003 received tamsulosin hydrochloride capsules 0.4 mg once daily, 491 received tamsulosin hydrochloride capsules 0.8 mg once daily, and 802 were control patients) in the U.S. and Europe.

In the two U.S. placebo-controlled, double-blind, 13-week, multicenter studies [Study 1 (US92-03A) and Study 2 (US93-01)], 1486 men with the signs and symptoms of BPH were enrolled. In both studies, patients were randomized to either placebo, tamsulosin hydrochloride capsules 0.4 mg once daily, or tamsulosin hydrochloride capsules 0.8 mg once daily. Patients in tamsulosin hydrochloride capsules 0.8 mg once-daily treatment groups received a dose of 0.4 mg once daily for one week before increasing to the 0.8 mg once-daily dose. The primary efficacy assessments included: 1) total American Urological Association (AUA) Symptom Score questionnaire, which evaluated irritative (frequency, urgency, and nocturia), and obstructive (hesitancy, incomplete emptying, intermittency, and weak stream) symptoms, where a decrease in score is consistent with improvement in symptoms; and 2) peak urine flow rate, where an increased peak urine flow rate value over baseline is consistent with decreased urinary obstruction.

Mean changes from baseline to Week 13 in total AUA Symptom Score were significantly greater for groups treated with tamsulosin hydrochloride capsules 0.4 mg and 0.8 mg once daily compared to placebo in both U.S. studies (Table 3, Figures 2A and 2B). The changes from baseline to Week 13 in peak urine flow rate were also significantly greater for the tamsulosin hydrochloride capsules 0.4 mg and 0.8 mg once-daily groups compared to placebo in Study 1, and for the tamsulosin hydrochloride capsules 0.8 mg once-daily group in Study 2 (Table 3, Figures 3A and 3B). Overall there were no significant differences in improvement observed in total AUA Symptom Scores or peak urine flow rates between the 0.4 mg and the 0.8 mg dose groups with the exception that the 0.8 mg dose in Study 1 had a significantly greater improvement in total AUA Symptom Score compared to the 0.4 mg dose.
OBJECTIVE: To study the effect of ERAS on a textbook outcome (TO) after elective renal surgery.
PATIENTS AND METHODS: Retrospective study of all patients who underwent a robot-assisted laparoscopic partial or radical nephrectomy or robot-assisted laparoscopic radical nephroureterectomy in Medisch Spectrum Twente (MST), Enschede, the Netherlands. In total, 277 patients were included. 66 patients from 2018 to 2021 (pre-ERAS group) and 211 patients from 2021 to 2023 (ERAS group). TO is a maximum of two nights in the hospital after surgery, no severe complications during or after surgery ≥ grade IIIb, no blood transfusions, no intensive care, no readmissions, and no mortality within 30 days after surgery. Comparisons were made between the pre-ERAS and ERAS groups using unpaired t-test, Mann-Whitney U test, the chi-squared test or Fisher's exact test. Multivariate logistic regression was used to adjust for possible confounding.
RESULTS: TO was significantly (p = 0.005) better in the ERAS group (TO = 76.8%) compared to the pre-ERAS group (TO = 59.1%). Compared to a pre-ERAS patient, the adjusted odds ratio for achieving a TO as an ERAS patient is 2.1 (95% CI 1.15-3.78).
CONCLUSIONS: The implementation of ERAS showed a positive effect on the TO of elective renal surgery patients.
In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.
This is a phase II study of an investigational drug, Axitinib following prior antiangiogenic therapy in patients with advanced hepatocellular carcinoma. Hepatocellular carcinoma (HCC) is a primary cancer of the liver. Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vessels. A tyrosine kinase is an enzyme that can inhibit angiogenesis. In this study, patients with advanced HCC who have failed prior antiangiogenic therapy, will receive Axitinib in cycles of 4 weeks. Axitinib is an oral, potent and selective inhibitor of angiogenesis. This study will evaluate the response rate of HCC following treatment with Axitinib as well as safety, feasibility, overall survival of patients, progression-free survival, and quality of life in persons with unresectable HCC. The study also compares response determined by RECIST to response determined by Choi Criteria.